HC-4955 / Hinova Pharma - LARVOL DELTA

Discovery of HC-4955, a novel AR-V7-targeting PROTAC for the treatment of mCRPC (AACR 2024) - "Next generation hormonal agents (NHAs) enzalutamide and abiraterone have brought clinical benefits for metastatic castrate-resistant prostate cancer (mCRPC) patients, AR axis-targeted therapy resistance is inevitable due to AR gene amplification or mutations. The pre-clinical results support the clinical development of HC-4955 for the treatment of mCRPC. Selected pre-clinical data along with the chemical structure of HC-4955 will be presented."

Late-breaking abstract • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • AR